Christos Sotiriou

79.1k total citations · 16 hit papers
366 papers, 29.1k citations indexed

About

Christos Sotiriou is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Christos Sotiriou has authored 366 papers receiving a total of 29.1k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Oncology, 200 papers in Cancer Research and 125 papers in Molecular Biology. Recurrent topics in Christos Sotiriou's work include Breast Cancer Treatment Studies (130 papers), HER2/EGFR in Cancer Research (97 papers) and Cancer Genomics and Diagnostics (87 papers). Christos Sotiriou is often cited by papers focused on Breast Cancer Treatment Studies (130 papers), HER2/EGFR in Cancer Research (97 papers) and Cancer Genomics and Diagnostics (87 papers). Christos Sotiriou collaborates with scholars based in Belgium, United States and Italy. Christos Sotiriou's co-authors include Martine Piccart, Christine Desmedt, Sherene Loi, Lajos Pusztai, Benjamin Haibe‐Kains, Denis Larsimont, Adrian L. Harris, Evandro de Azambuja, Fátima Cardoso and Michail Ignatiadis and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Christos Sotiriou

343 papers receiving 28.6k citations

Hit Papers

Breast cancer classification and prognosis based on gene ... 2003 2026 2010 2018 2003 2006 2011 2013 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast cancer classification and prognosis based on gene expression profiles from a population-based study
    2003 1.5k citations Christos Sotiriou, Amir A. Jazaeri et al. profile →
  2. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
    2006 1.5k citations Christos Sotiriou, Sherene Loi et al. profile →
  3. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
    2011 1.5k citations Christos Sotiriou et al. profile →
  4. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
    2013 1.2k citations Sherene Loi, Nicolas Sirtaine et al. Journal of Clinical Oncology profile →
  5. Gene-Expression Signatures in Breast Cancer
    2009 1.1k citations Christos Sotiriou, Lajos Pusztai profile →
  6. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    2014 956 citations Sherene Loi, Stefan Michiels et al. Annals of Oncology profile →
  7. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
    2006 842 citations Sherene Loi, Giuseppe Viale et al. profile →
  8. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series
    2007 726 citations Christine Desmedt, Fanny Piette et al. Clinical Cancer Research profile →
  9. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    2007 724 citations Evandro de Azambuja, Fátima Cardoso et al. profile →
  10. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    2008 654 citations Christos Sotiriou, Benjamin Haibe‐Kains et al. profile →
  11. Clinical relevance of host immunity in breast cancer: from TILs to the clinic
    2015 638 citations Roberto Salgado, Christos Sotiriou et al. Nature Reviews Clinical Oncology profile →
  12. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
    2008 601 citations Christine Desmedt, Benjamin Haibe‐Kains et al. Clinical Cancer Research profile →
  13. Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
    2007 599 citations Sherene Loi, Benjamin Haibe‐Kains et al. Journal of Clinical Oncology profile →
  14. The 2019 World Health Organization classification of tumours of the breast
    2020 547 citations Roberto Salgado, Christos Sotiriou et al. profile →
  15. hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer
    2008 540 citations Christos Sotiriou, Adrian L. Harris et al. Clinical Cancer Research profile →
  16. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
    2015 432 citations Roberto Salgado, Paolo Nucíforo et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christos Sotiriou Belgium 76 15.6k 13.8k 12.3k 4.4k 3.2k 366 29.1k
Jonas Bergh Sweden 73 15.6k 1.0× 11.6k 0.8× 11.2k 0.9× 4.9k 1.1× 2.1k 0.7× 521 29.1k
Carsten Denkert Germany 79 15.3k 1.0× 11.3k 0.8× 11.5k 0.9× 4.4k 1.0× 3.9k 1.2× 522 29.5k
Lars A. Akslen Norway 67 14.0k 0.9× 11.6k 0.8× 13.8k 1.1× 4.4k 1.0× 2.0k 0.6× 314 29.1k
Lajos Pusztai United States 87 20.1k 1.3× 16.9k 1.2× 12.1k 1.0× 5.7k 1.3× 3.0k 0.9× 591 35.0k
Joel S. Parker United States 72 11.4k 0.7× 13.2k 1.0× 16.2k 1.3× 4.3k 1.0× 2.3k 0.7× 278 29.7k
Torsten O. Nielsen Canada 77 16.1k 1.0× 14.5k 1.1× 10.3k 0.8× 7.7k 1.7× 2.0k 0.6× 241 31.1k
Stephen B. Fox Australia 84 13.0k 0.8× 10.4k 0.8× 14.2k 1.2× 4.7k 1.1× 3.1k 1.0× 423 29.3k
Charles Swanton United Kingdom 79 12.8k 0.8× 12.7k 0.9× 13.0k 1.1× 8.5k 1.9× 2.9k 0.9× 325 30.6k
Thérese Sørlie Norway 34 15.0k 1.0× 15.0k 1.1× 16.2k 1.3× 3.8k 0.9× 1.3k 0.4× 92 31.0k
Stefanie S. Jeffrey United States 51 13.8k 0.9× 14.9k 1.1× 16.6k 1.4× 3.9k 0.9× 1.3k 0.4× 138 33.6k

Countries citing papers authored by Christos Sotiriou

Since Specialization
Citations

This map shows the geographic impact of Christos Sotiriou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christos Sotiriou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christos Sotiriou more than expected).

Fields of papers citing papers by Christos Sotiriou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christos Sotiriou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christos Sotiriou. The network helps show where Christos Sotiriou may publish in the future.

Co-authorship network of co-authors of Christos Sotiriou

This figure shows the co-authorship network connecting the top 25 collaborators of Christos Sotiriou. A scholar is included among the top collaborators of Christos Sotiriou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christos Sotiriou. Christos Sotiriou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buisseret, Laurence, Yacine Barèche, David Venet, et al.. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open. 9(5). 102964–102964. 4 indexed citations
2.
Rediti, Mattia, David Venet, Samira Majjaj, et al.. (2023). Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00. Clinical Cancer Research. 29(23). 4908–4919. 7 indexed citations
3.
Pondé, Noam, Dominique Agbor‐Tarh, Lissandra Dal Lago, et al.. (2020). Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Research and Treatment. 185(1). 107–116. 4 indexed citations
4.
Powles, Ryan L., David Redmond, Christos Sotiriou, et al.. (2018). Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology. 4(11). e181564–e181564. 13 indexed citations
5.
Turcotte, Martin, David Allard, Deepak Mittal, et al.. (2017). CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research. 77(20). 5652–5663. 94 indexed citations
6.
Loi, Sherene, Urania Dafni, Dimitris Karlis, et al.. (2016). Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. 2(8). 1040–1040. 65 indexed citations
7.
Mittal, Deepak, Franco Caramia, Stefan Michiels, et al.. (2016). Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research. 76(2). 264–274. 23 indexed citations
8.
Božović‐Spasojević, Ivana, Dimitrios Zardavas, Sylvain Brohée, et al.. (2016). The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. Clinical Cancer Research. 23(11). 2702–2712. 84 indexed citations
9.
Gingras, Isabelle, Christine Desmedt, Michail Ignatiadis, & Christos Sotiriou. (2015). CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?. Clinical Cancer Research. 21(21). 4743–4746. 18 indexed citations
10.
Sonnenblick, Amir, Debora Fumagalli, Christos Sotiriou, & Martine Piccart. (2014). Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. Cancer Treatment Reviews. 40(9). 1089–1095. 25 indexed citations
11.
Fumagalli, Debora, Alexis Blanchet-Cohen, David N. Brown, et al.. (2014). Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics. 15(1). 1008–1008. 42 indexed citations
12.
Ades, Felipe, Dimitrios Zardavas, Ivana Božović‐Spasojević, et al.. (2014). Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of Clinical Oncology. 32(25). 2794–2803. 292 indexed citations
13.
Azambuja, Evandro de, Dimitrios Zardavas, Marc Lemort, et al.. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of Oncology. 24(12). 2985–2989. 21 indexed citations
14.
Loi, Sherene, Nicolas Sirtaine, Fanny Piette, et al.. (2013). Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology. 31(7). 860–867. 1213 indexed citations breakdown →
15.
Metzger, Otto, Andrew Tutt, Evandro de Azambuja, et al.. (2012). Dissecting the Heterogeneity of Triple-Negative Breast Cancer. Journal of Clinical Oncology. 30(15). 1879–1887. 356 indexed citations
16.
Azim, Hatem A., Stefan Michiels, Philippe L. Bédard, et al.. (2012). Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. Clinical Cancer Research. 18(5). 1341–1351. 278 indexed citations
17.
Ignatiadis, Michail & Christos Sotiriou. (2011). Should we assess HER2 status by Oncotype DX®?. Nature Reviews Clinical Oncology. 9(1). 12–14. 8 indexed citations
18.
Ignatiadis, Michail, Françoise Rothé, Carole Chaboteaux, et al.. (2011). HER2-Positive Circulating Tumor Cells in Breast Cancer. PLoS ONE. 6(1). e15624–e15624. 159 indexed citations
19.
Ma, Xiaojun, Ranelle Salunga, Sonika Dahiya, et al.. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research. 14(9). 2601–2608. 227 indexed citations
20.
Jazaeri, Amir A., Christopher S. Awtrey, Gadisetti V.R. Chandramouli, et al.. (2005). Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers. Clinical Cancer Research. 11(17). 6300–6310. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Carsten Denkert Breakdown of academic impact, for papers by Lars A. Akslen Breakdown of academic impact, for papers by Lajos Pusztai Breakdown of academic impact, for papers by Joel S. Parker Breakdown of academic impact, for papers by Torsten O. Nielsen Breakdown of academic impact, for papers by Stephen B. Fox Breakdown of academic impact, for papers by Charles Swanton Breakdown of academic impact, for papers by Thérese Sørlie Breakdown of academic impact, for papers by Stefanie S. Jeffrey
Rankless by CCL
2026